Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Novacyt  /  Novacyt de volgende biotech raket!

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

  • 0,788 10 mei 2024 17:35
  • -0,009 (-1,13%) Dagrange 0,778 - 0,800
  • 87.302 Gem. (3M) 188,3K

Novacyt de volgende biotech raket!

70.383 Posts
Pagina: «« 1 ... 1032 1033 1034 1035 1036 ... 3520 »» | Laatste | Omlaag ↓
  6. SanStock 4 juni 2020 09:11


    Novacyt SA (LON:NCYT) shares slipped on Tuesday after the diagnostics firm said its polymerase chain reaction (PCR) test for coronavirus will not be reimbursed by regulators in France.

    In an update, the AIM-listed group said the Haute Autorité de Santé (HAS), which advises the French government on medical reimbursement, had not approved the test for reimbursement in the country on the basis that the test has been developed with one single gene target. However, the company will be able to sell the test in France for private patient testing.

    "Despite the decision from HAS not to reimburse our [coronavirus] test, we will continue to offer the test for private patient testing and evaluate new ways of supporting the French market. Our manufacturing scale-up is progressing to plan and we look forward to supporting current and additional countries with their testing requirements", said Novacyt chief executive Graham Mullis.

    Away from the setback in France, the company reported that as of June 1 sales of the PCR test were £40mln and that its molecular diagnostics division, Primerdesign, has received orders to deliver a further £80mln-worth of the test, taking total sales and confirmed orders to £120mln.

    The firm also said additional coronavirus-related sales are expected in the second half of the year from its new products, Exsig Direct and Exsig Mag, as well as from its mobile testing solution.

    The Exsign products are on track to launch in June while the mobile testing system will launch in July.

    Meanwhile, Novacyt said Primerdesign has been awarded a contract from Zimbabwe's Ministry of Health and Child Care to supply 1.5mln coronavirus tests, the largest order secured to date outside the UK.

    The firm said the initial purchase order for 500,000 tests has been received and will be shipped immediately, with the remaining tests to be shipped over the coming weeks.

    Novacyt said it is now selling the coronavirus test in over 130 countries, adding that over the last few weeks it has secured registrations and regulatory approvals for the test in Panama, Ecuador, Columbia, Peru, Paraguay and the UAE.

    "We are encouraged by the increasing number of new markets validating our [coronavirus] test for clinical use, which can be seen in the significant increase in sales and order commitments received to date. The competitive tender process and subsequent award in Zimbabwe to support the country's national [coronavirus] testing effort is a key example of our increasing global reach. As new regions are impacted by the pandemic, we expect the demand for our [coronavirus] test to continue to grow”, Mullis said.

    Shares in Novacyt were 3.7% lower at 322.8p in early trading.
  10. [verwijderd] 4 juni 2020 09:13
    quote:

    Zaga101 schreef op 4 juni 2020 09:10:

    Durft er eigenlijk iemand bijkopen?
    Sinds we onder de 3,2 EUR zijn gezakt is het moeilijk om een nieuwe bodem te bepalen.
    Waar leggen jullie deze momenteel? (serieuze vraag, dus graag ook serieus antwoord ;-))
    ik denk persoonlijk dat 2 EUR het volgende dieptepunt wordt.
    Maar ik vermoed ook wel dat er vandaag redelijk wordt bijgekocht. Het daalt al 3 dagen sterk, dus de mensen die willen verkopen hebben dit al gedaan volgens mij.
  12. SanStock 4 juni 2020 09:13
    Dit is van gisteren:

    Clinical diagnostics company Novacyt will settle all outstanding debt obligations with Harbert European Growth Capital (HEGC) and Vatel Capital, it announced on Wednesday.

    The AIM-traded firm said that under the arrangements, it would clear its debt obligations with HEGC and Vatel before the end of June.

    In doing so, it would settle a total of €7m (£6.23m) of principal debt provided by the two lenders.

    The €5m HEGC secured term loan, announced on 6 November, has a fixed interest rate of 11% per annum and is repayable over 48 months, with an initial 12-month interest only period followed by 36 equal monthly payments of interest and capital.

    HEGC took a first ranking charge over the assets of the UK businesses with a pledge over Novacyt, which would be satisfied on full repayment of €6.1m, including €5m of capital, during June.

    In May 2018, Novacyt entered into an unsecured convertible bond facility with Vatel for €4m to be repaid over three years at an interest rate of 7.4%.

    Under the terms of an agreed restructure with Vatel, announced on 6 November, the interest rate was retrospectively increased to 8.9% effective 31 July 2019, and the term of the loan was extended by 12 months to May 2022, to reduce annual payments to Vatel.

    The bond also carries a non-conversion premium of 0.1% when monthly repayments are made in cash.

    Novacyt said Vatel had exercised its right to request conversion of all outstanding debt into new ordinary shares at a fixed conversion price of 70 euro cents each.

    Thus, the remaining debt of €2.07m was converted into 2,952,681 ordinary shares, and no future or accrued interest would be payable as a result of the conversion.

    Vatel agreed to a lock-in period for a certain number of the shares, under which 1,107,255 of them would not be sold or transferred before 31 December 2021, and a further 1,033,438 would not be sold or transferred before 31 March 2021.

    The remaining 811,988 shares had no such restrictions.

    Novacyt said the early settlement of the HEGC loan was being funded out of general cash resources.

    As at 2 June, prior to the payment to HEGC, the group had a net cash balance of €25m, up from €1.8m at the end of December.

    “We are pleased to announce early settlement of all of Novacyt's outstanding debt obligations, which has been made possible due to the company's strong cash generation so far in 2020,” said chief executive officer Graham Mullis.

    “With significant order commitments and raw materials acquired for our Covid-19 test, and expected revenues from new products, we expect strong cash generation to continue.

    “I would like to extend my thanks to HEGC and Vatel for supporting Novacyt during this time.”

    At 1225 BST, shares in Novacyt were down 2.61% at 298p.
  14. Rookie01 4 juni 2020 09:14
    quote:

    trab33 schreef op 4 juni 2020 09:11:

    wou toch melden dat ik mijn totaal verdubbeld heb aan 2.77
    succes ieder met zijn beslissingen
    edit
    toch terug te vroeg zie ik maar het is wat het is de eindmeet is belangrijkst
    Er is geen enkel positief signaal meer, geen reactie op persberichten we gaan echt niet zomaar uit het niets stijgen hoor.
70.383 Posts
Pagina: «« 1 ... 1032 1033 1034 1035 1036 ... 3520 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!